Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A Tangible Net Worth Ratio
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A tangible net worth ratio. Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) has a Tangible Net Worth Ratio of 97.0% as of March 2026. This metric is calculated by deducting intangible assets (CN¥51.55 Million) from net assets (CN¥1.71 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore how fast is Shaanxi Panlong Pharmaceutical Group Lim growing its equity to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (2013–2025)
Tangible net worth ratio of Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A from 2013 to 2025. This chart shows how Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's Tangible Net Worth Ratio has changed across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 97.0%, reflecting net assets of CN¥1.71 Billion with intangible assets of CN¥51.55 Million CNY. Check Shaanxi Panlong Pharmaceutical Group Lim (002864) strategic investment index to assess the company's strategic physical and investment asset allocation.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A Tangible Net Worth Ratio by Year (2013–2025)
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A tangible net worth ratio by year from 2013 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A from 2013 to 2025, covering 13 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Shaanxi Panlong Pharmaceutical Group Lim market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 96.9% | CN¥1.69 Billion | CN¥51.93 Million | CN¥2.32 Billion | ▲ +0.1 pp |
| 2024 | 96.9% | CN¥1.64 Billion | CN¥51.35 Million | CN¥2.28 Billion | ▲ +0.3 pp |
| 2023 | 96.6% | CN¥1.55 Billion | CN¥52.76 Million | CN¥2.13 Billion | ▲ +2.4 pp |
| 2022 | 94.2% | CN¥947.60 Million | CN¥54.90 Million | CN¥1.93 Billion | ▲ +1.2 pp |
| 2021 | 93.0% | CN¥807.21 Million | CN¥56.33 Million | CN¥1.33 Billion | ▲ +0.9 pp |
| 2020 | 92.1% | CN¥735.66 Million | CN¥57.77 Million | CN¥1.16 Billion | ▲ +0.9 pp |
| 2019 | 91.2% | CN¥674.71 Million | CN¥59.38 Million | CN¥928.88 Million | ▲ +1.2 pp |
| 2018 | 90.0% | CN¥611.60 Million | CN¥60.98 Million | CN¥817.84 Million | ▲ +1.3 pp |
| 2017 | 88.7% | CN¥555.58 Million | CN¥62.59 Million | CN¥752.93 Million | ▲ +8.3 pp |
| 2016 | 80.5% | CN¥327.82 Million | CN¥64.03 Million | CN¥504.50 Million | ▲ +2.7 pp |
| 2015 | 77.8% | CN¥288.89 Million | CN¥64.24 Million | CN¥433.33 Million | ▼ -8.7 pp |
| 2014 | 86.4% | CN¥246.19 Million | CN¥33.43 Million | CN¥401.26 Million | ▼ -7.8 pp |
| 2013 | 94.2% | CN¥210.84 Million | CN¥12.15 Million | CN¥342.39 Million | — |